Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer

Qingqing Huang,Mingcheng Liu,Duo Zhang,Bing-Biao Lin,Xing Fu,Zhiqian Zhang,Baotong Zhang,Jin-Tang Dong
DOI: https://doi.org/10.1186/s12916-023-02763-4
IF: 9.3
2023-02-23
BMC Medicine
Abstract:Castration-resistant prostate cancer often metastasizes to the bone, and such bone metastases eventually become resistant to available therapies, leading to the death of patients. Enriched in the bone, TGF-β plays a pivotal role in bone metastasis development. However, directly targeting TGF-β or its receptors has been challenging for the treatment of bone metastasis. We previously found that TGF-β induces and then depends on the acetylation of transcription factor KLF5 at K369 to regulate multiple biological processes, including the induction of EMT, cellular invasiveness, and bone metastasis. Acetylated KLF5 (Ac-KLF5) and its downstream effectors are thus potential therapeutic targets for treating TGF-β-induced bone metastasis in prostate cancer.
medicine, general & internal
What problem does this paper attempt to address?